Biohaven Ltd. BHVN
At closeNov 5, 2026, 7:17 PM EST
After hours · Nov 5, 7:17 PM ET
- YTD
- +23.12%
- 1 year
- +66.67%
- Market cap
- 2.10B
- EPS (ttm)
- -3.44
- Shares out
- 151.06M
- Forward P/E
- -7.44
- YTD return
- +23.12%
- 1-year return
- +66.67%
- Volume
- 3.47M
- Avg volume
- 3.18M
- Open
- 15.11
- Previous close
- 15.24
- Day's range
- 13.95 – 15.11
- 52-week range
- 7.48 – 18.24
- Beta
- 3.13
- Analysts
- Buy
- Price target
- 23.73 (+70.7%)
- Earnings date
- Mar 1, 2027
1M +1.80 (+14.90%)
Key statistics
- Enterprise value
- 2.44B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -229.34M
- Total cash
- 161.12M
- Total debt
- 300.44M
- Return on equity
- 0.00%
- Short % of float
- 15.16%
- 50-day average
- 13.71
- 200-day average
- 12.27
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 23.73
- Target (high)
- 48.00
- Strong buy3
- Buy9
- Hold4
- Sell0
- Strong sell1
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 0.60338.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.2536 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | -0.78333 | -0.86 | -0.08 | -9.79% |
| Aug 10, 2026 | Jun 30, 2026 | -0.76098 | -0.91 | -0.15 | -19.58% |
| May 4, 2026 | Mar 31, 2026 | -0.86 | -0.88 | -0.02 | -2.33% |
| Mar 2, 2026 | Dec 31, 2025 | -1.22 | -1.21 | +0.01 | +0.82% |
| Nov 10, 2025 | Sep 30, 2025 | -1.91 | -1.64 | +0.27 | +14.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 3, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Oct 30, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 23, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 8, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Aug 12, 2026 | Morgan Stanley | main | Overweight | Overweight |
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- biohaven.com
News
Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EU 
Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting 
Morgan Stanley Maintains Overweight on Biohaven, Raises Price Target to $21 
Canaccord Genuity Maintains Buy on Biohaven, Raises Price Target to $32 
Biohaven Q3 Adj. EPS $(0.73) Beats $(0.74) Estimate 
Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results 
Wall Street Analysts Believe Biohaven Ltd. (BHVN) Could Rally 43.49%: Here's is How to Trade 
Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026 
Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy 
RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22
Your note
Sign in to keep a note on BHVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Nov 12, 2025 | 2,020,070 |
| BUTEN MATTHEW | Chief Financial Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 195,652 |
| CAR BRUCE | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 37,715 |
| CHILDS JOHN W | Director | Purchase | Nov 12, 2025 | 0 |
| CLARK GEORGE C. | Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 86,978 |
| CORIC VLADIMIR | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 3,849,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.75% | 13,210,585 | 183.36M | Jun 29, 2026 |
| Montanova Capital LLC | 6.81% | 10,286,937 | 142.78M | Jun 29, 2026 |
| Stifel Financial Corporation | 6.58% | 9,941,165 | 137.98M | Jun 29, 2026 |
| Jupiter Topco LLC | 5.68% | 8,584,675 | 119.16M | Jun 29, 2026 |
| Woodline Partners LP | 5.07% | 7,660,280 | 106.32M | Jun 29, 2026 |
| State Street Corporation | 4.60% | 6,947,034 | 96.42M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 3,699,312 | 51.35M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.29% | 3,455,073 | 47.96M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.41% | 2,130,196 | 29.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.99% | 1,489,215 | 20.67M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.97% | 1,468,076 | 20.38M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.83% | 1,248,218 | 17.33M | Sep 29, 2026 |